进行性纤维化型间质性肺疾病合并肺癌相关机制研究及进展  

Research and progress on the mechanism of progressive fibrotic interstitial lung disease combined with lung cancer

作　　者：赵雅茹 高俊珍[1] Zhao Yaru;Gao Junzhen(Department of Respiratory and Critical Care Medicine,the Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010000,China)

机构地区：[1]内蒙古医科大学附属医院呼吸与危重症医学科,呼和浩特010000

出　　处：《国际呼吸杂志》2023年第5期610-614,共5页International Journal of Respiration

基　　金：北京肿瘤防治研究会CAPTRA-Lung科研基金(CAPTRALung2022003)。

摘　　要：间质性肺疾病(ILD)是一种病因众多, 异质性强的弥漫性肺实质损伤疾病。近年来, 不同类型ILD很明显有发展为进行性肺纤维化的风险, 此类ILD被称为进行性纤维化型间质性肺疾病(PF-ILD), 其表现类似于特发性肺纤维化(IPF)。PF-ILD不是一个独特的临床疾病, 而是描述了一组具有相似临床特征的ILD, 其中IPF为典型例子。IPF合并肺癌发生率较高, 在IPF及肺癌发展过程中有共同的信号途径、细胞因子及蛋白表达等。然而, 关于其具体发病机制和治疗仍有许多未知数。本文简要回顾了目前流行病学、相关机制和潜在治疗前景有关的研究进展。Interstitial lung disease(ILD)is associated with diffuse parenchymal lung injury with numerous and heterogeneous etiologies.In recent years,it has become evident that patients with different types of ILD are at risk of developing progressive pulmonary fibrosis,which is referred to as progressive fibrotic ILD(PF-ILD),having a similar presentation to idiopathic pulmonary fibrosis(IPF).PF-ILD is not a distinct clinical disease but describes a group of ILDs with similar clinical behaviour,especially IPF as typical.The incidence of IPF combined with lung cancer is high,and there are common signaling pathways,cytokines,and protein expressions in the development of IPF and lung cancer,however,there are still many unknowns about their specific pathogenesis and treatment.This paper briefly reviews the current epidemiology,related mechanisms and current research progress related to potential therapeutic prospects.

关 键 词：肺疾病 间质性 肺肿瘤 发病机制 治疗 

分 类 号：R563[医药卫生—呼吸系统] R734.2[医药卫生—内科学]